To investigate the effect of Xinnaoning Capsules on angina pectoris in patients with coronary heart disease(CHD) after percutaneous coronary intervention(PCI).Methods:A total of 132 CHD patients with varying degrees of angina pectoris after PCI，admitted to the Department of Cardiovascular Medicine at Hebei Provincial Hospital of Traditional Chinese Medicine between May 2021 and March 2022，were enrolled and divided into a control group and an observation group by simple randomization(coin tossing)，with 66 patients in each group.Both groups received conventional western medicine treatment.The control group was given a placebo，while the observation group received Xinnaoning Capsules orally.The incidence of angina attacks，the reduction and discontinuation rate of nitroglycerin，blood lipid levels，plaque area，Seattle Angina Questionnaire scores，and adverse reactions were compared before and after treatment between the two groups.Results:After 24 weeks of treatment，both groups showed significant improvement in the incidence of angina attacks，nitroglycerin reduction and discontinuation rates，triglycerides，total cholesterol，and low-density lipoprotein cholesterol levels compared to the conditions before treatment，with the observation group showing more significant improvement(all P<0.05).After treatment，both groups also showed improvements in physical activity limitations，stability of angina，incidence of angina attacks，treatment satisfaction，and disease awareness(all P<0.05).Conclusion:Xinnaoning Capsules combined with western medicine in the short-term treatment of angina pectoris in CHD patients after PCI can reduce the frequency and duration of angina attacks，decrease the use of anti-angina medications，and effectively control blood lipid levels，with few adverse reactions.